Key facts
- This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
- 6 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Jun 2026, 16:10.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Sale
Sale
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026.
Footnote F2
Includes 51,388 restricted stock units.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $166.76 to $167.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F4
This transaction was executed in multiple trades at prices ranging from $167.77 to $168.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F5
This transaction was executed in multiple trades at prices ranging from $168.78 to $169.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F6
This transaction was executed in multiple trades at prices ranging from $169.81 to $170.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.